E Carrillo

List of Publications by Year in Descending Order

53 papers	1,263 citations	20 h-index	34 g-index
62 ext. papers	1,580 ext. citations	5.6 avg, IF	4.3 L-index

#	Paper	IF	Citations
53	Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant. *Microorganisms*, **2021**, 9,	4.9	3
52	Detection of cutaneous leishmaniasis in three communities of Oti Region, Ghana. *PLoS Neglected Tropical Diseases*, **2021**, 15, e0009416	4.8	2
51	Effect of immunosuppressants on the parasite load developed in, and immune response to, visceral leishmaniasis: A comparative study in a mouse model. *PLoS Neglected Tropical Diseases*, **2021**, 15, e0009126	4.8	
50	Leishmaniasis: A new method for confirming cure and detecting asymptomatic infection in patients receiving immunosuppressive treatment for autoimmune disease. *PLoS Neglected Tropical Diseases*, **2021**, 15, e0009662	4.8	1
49	Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases. *Seminars in Immunopathology*, **2020**, 42, 231-246	12	15
48	Whole Blood Stimulation Assay as a Treatment Outcome Monitoring Tool for VL Patients in Ethiopia: A Pilot Evaluation. *Journal of Immunology Research*, **2020**, 2020, 8385672	4.5	0
47	Role of asymptomatic and symptomatic humans as reservoirs of visceral leishmaniasis in a Mediterranean context. *PLoS Neglected Tropical Diseases*, **2020**, 14, e0008253	4.8	14
46	Molecular identification of and isolated from cutaneous human leishmaniasis samples in central Morocco. *Journal of Vector Borne Diseases*, **2020**, 57, 71-77	0.7	1
45	New Strategies and Biomarkers for the Control of Visceral Leishmaniasis. *Trends in Parasitology*, **2020**, 36, 29-38	6.4	9
44	Asymptomatic immune responders to Leishmania among HIV positive patients. *PLoS Neglected Tropical Diseases*, **2019**, 13, e0007461	4.8	11
43	Clinical aspects of visceral leishmaniasis caused by L. infantum in adults. Ten years of experience of the largest outbreak in Europe: what have we learned?. *Parasites and Vectors*, **2019**, 12, 359	4	15
42	A multicentric evaluation of dipstick test for serodiagnosis of visceral leishmaniasis in India, Nepal, Sri Lanka, Brazil, Ethiopia and Spain. *Scientific Reports*, **2019**, 9, 9932	4.9	8
41	The Use of Specific Serological Biomarkers to Detect CaniLeish Vaccination in Dogs. *Frontiers in Veterinary Science*, **2019**, 6, 373	3.1	4
40	Prevalence of asymptomatic infection and associated risk factors, after an outbreak in the south-western Madrid region, Spain, 2015. *Eurosurveillance*, **2019**, 24,	19.8	18
39	Asymptomatic carriers of Leishmania infantum in patients infected with human immunodeficiency virus (HIV) in Morocco. *Parasitology Research*, **2018**, 117, 1237-1244	2.4	12
38	Evaluation of fluorimetry and direct visualization to interpret results of a loop-mediated isothermal amplification kit to detect Leishmania DNA. *Parasites and Vectors*, **2018**, 11, 250	4	18
37	Antigenicity of -Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters. *Frontiers in Immunology*, **2018**, 9, 843	8.4	5

36	Can artificial tears prevent Acanthamoeba keratitis? An in vitro approach. *Parasites and Vectors*, **2018**, 11, 50	4	2
35	Cellular Markers of Active Disease and Cure in Different Forms of -Induced Disease. *Frontiers in Cellular and Infection Microbiology*, **2018**, 8, 381	5.9	9
34	Potentiation of the leishmanicidal activity of nelfinavir in combination with miltefosine or amphotericin B. *International Journal of Antimicrobial Agents*, **2018**, 52, 682-687	14.3	6
33	Infectivity of Post-Kala-azar Dermal Leishmaniasis Patients to Sand Flies: Revisiting a Proof of Concept in the Context of the Kala-azar Elimination Program in the Indian Subcontinent. *Clinical Infectious Diseases*, **2017**, 65, 150-153	11.6	51
32	Efficacies of prevention and control measures applied during an outbreak in Southwest Madrid, Spain. *PLoS ONE*, **2017**, 12, e0186372	3.7	7
31	Molecular detection of Leishmania infantum and Leishmania tropica in rodent species from endemic cutaneous leishmaniasis areas in Morocco. *Parasites and Vectors*, **2017**, 10, 454	4	21
30	Environmental Factors as Key Determinants for Visceral Leishmaniasis in Solid Organ Transplant Recipients, Madrid, Spain. *Emerging Infectious Diseases*, **2017**, 23, 1155-1159	10.2	9
29	Cytokines and chemokines measured in dried SLA-stimulated whole blood spots for asymptomatic Leishmania infantum and Leishmania donovani infection. *Scientific Reports*, **2017**, 7, 17266	4.9	9
28	IFN-IL-2, IP-10, and MIG as Biomarkers of Exposure to spp., and of Cure in Human Visceral Leishmaniasis. *Frontiers in Cellular and Infection Microbiology*, **2017**, 7, 200	5.9	28
27	Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis. *Frontiers in Immunology*, **2017**, 8, 227	8.4	16
26	F1 Domain of the Nucleoside Hydrolase Promotes a Th1 Response in Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis. *Frontiers in Immunology*, **2017**, 8, 750	8.4	12
25	Monocyte Chemotactic Protein 1 in Plasma from Soluble Antigen-Stimulated Whole Blood as a Potential Biomarker of the Cellular Immune Response to. *Frontiers in Immunology*, **2017**, 8, 1208	8.4	12
24	Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005951	4.8	27
23	Lymphoproliferative response after stimulation with soluble leishmania antigen (SLA) as a predictor of visceral leishmaniasis (VL) relapse in HIV+ patients. *Acta Tropica*, **2016**, 164, 345-351	3.2	9
22	Impact of Helminth Infection on the Clinical and Microbiological Presentation of Chagas Diseases in Chronically Infected Patients. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0004663	4.8	13
21	Compartmentalized Immune Response in Leishmaniasis: Changing Patterns throughout the Disease. *PLoS ONE*, **2016**, 11, e0155224	3.7	19
20	Interleukin-27 Early Impacts Infection in Mice and Correlates with Active Visceral Disease in Humans. *Frontiers in Immunology*, **2016**, 7, 478	8.4	12
19	Seroepidemiology and molecular diversity of Leishmania donovani complex in Georgia. *Parasites and Vectors*, **2016**, 9, 279	4	6

18	Canine-Based Strategies for Prevention and Control of Visceral Leishmaniasis in Brazil. *PLoS ONE*, **2016**, 11, e0160058	3.7	32
17	Interleukin-2 as a marker for detecting asymptomatic individuals in areas where Leishmania infantum is endemic. *Clinical Microbiology and Infection*, **2016**, 22, 739.e1-4	9.5	23
16	Cytokine Release Assays as Tests for Exposure to Leishmania, and for Confirming Cure from Leishmaniasis, in Solid Organ Transplant Recipients. *PLoS Neglected Tropical Diseases*, **2015**, 9, e0004179	4.8	31
15	Leishmaniasis in immunosuppressed individuals. *Clinical Microbiology and Infection*, **2014**, 20, 286-99	9.5	206
14	Protein malnutrition impairs the immune response and influences the severity of infection in a hamster model of chronic visceral leishmaniasis. *PLoS ONE*, **2014**, 9, e89412	3.7	22
13	A randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naïve dogs exposed to two leishmania infantum transmission seasons. *PLoS Neglected Tropical Diseases*, **2014**, 8, e3213	4.8	67
12	In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis. *PLoS ONE*, **2014**, 9, e92708	3.7	28
11	Characterization of the biology and infectivity of Leishmania infantum viscerotropic and dermotropic strains isolated from HIV+ and HIV- patients in the murine model of visceral leishmaniasis. *Parasites and Vectors*, **2013**, 6, 122	4	31
10	An approach for interlaboratory comparison of conventional and real-time PCR assays for diagnosis of human leishmaniasis. *Experimental Parasitology*, **2013**, 134, 281-9	2.1	44
9	What is responsible for a large and unusual outbreak of leishmaniasis in Madrid?. *Trends in Parasitology*, **2013**, 29, 579-80	6.4	34
8	Fluorescent labeling of Acanthamoeba assessed in situ from corneal sectioned microscopy. *Biomedical Optics Express*, **2012**, 3, 2489-99	3.5	4
7	Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis. *Trends in Parasitology*, **2010**, 26, 341-9	6.4	82
6	Cytokine profiles in canine visceral leishmaniasis. *Veterinary Immunology and Immunopathology*, **2009**, 128, 67-70	2	54
5	Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. *Vaccine*, **2008**, 26, 1902-11	4.1	49
4	Serological evaluation of experimentally infected dogs by LicTXNPx-ELISA and amastigote-flow cytometry. *Veterinary Parasitology*, **2008**, 158, 23-30	2.8	13
3	Synthesis of BODIPY-labeled alkylphosphocholines with leishmanicidal activity, as fluorescent analogues of miltefosine. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 6336-9	2.9	33
2	Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis. *Vaccine*, **2007**, 25, 1534-43	4.1	35
1	Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. *Vaccine*, **2007**, 25, 5290-300	4.1	62